Table 1.
HCV prevalence data by country
| Country (2016 total population) | National anti-HCV prevalence estimate (%) | Adult anti-HCV prevalence Gower, et al. (%) | Estimated number of anti-HCV+ people | Estimated anti-HCV prevalence among PWID (%) | Estimated anti-HCV prevalence among PLHIV (%) | Key populations specified |
|---|---|---|---|---|---|---|
| Armenia (2994400) | 4 | 120,000 | 52.1 | 17.9 | Migrants, PWID | |
| Azerbaijan (9705600) | 3.2 | 3.1 | 300,800 | 62.8 | 5.9 | PWID |
| Belarus (9498700) | 2–3 | 1.3 | 250,000 | 70–95 | PWID | |
| Georgia (3720400) | 7.5 | 208,800 | 57–74 | 4.8 | PWID, MSM, healthcare workers | |
| Kazakhstan (17753200) | 1.5–3 | 3.3 | 255,000–510,000 | % not available (estimated 6049 people) | 4.5 | |
| Kyrgyzstan (6019500) | 4 | 2.5 | 220,000 | 45.2 | 80 | |
| Moldova (3553100) | 1.7–4 | 4.5 | 60,000–142,000 | 35.3–65.4 | 4.6 | PWID |
| Russia (146544710) | 4 | 4.1 | 5,900,000 | 69 | 27 | PWID |
| Tajikistan (8547000) | 2.3 | 3.1 | 200,000 | 22.7–49.3 | 25.6% among HIV+ PWID | PWID |
| Ukraine (42708647) | 5 | 2,135,000 | 55 | PWID; hemophiliacs, hemodialysis patients; MSM; PMTCT clients | ||
| Uzbekistan (31575300) | 6.5 | 1,800,000 | 36 | Healthcare workers, PWID, patients receiving invasive treatment |